drugset
drugset / Trial / NCT00455221

Safety Assessment of a Multipeptide-gene Vaccine in CML

NCT00455221 ↗

Phase 1 Completed 12 enrolled Tehran University of Medical Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety of a peptide-gene vaccine against CML in patients under Imatinib treatment. We will also perform some laboratory tests suggesting biological response.

Timeline

Start
2008-02
Primary completion
2010-12
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bcr-abl multipeptide vaccine Vaccine 100 ug Subcutaneous
Subject interleukin-12 Protein / enzyme biologic — Subcutaneous
Subject sargramostim Protein / enzyme biologic — Subcutaneous

Indications

chronic myeloid leukemia